simtuzumab

A humanized monoclonal antibody against lysyl oxidase-like 2 (LOXL2), with potential antineoplastic activity. Anti-LOXL2 monoclonal antibody GS 6624… (More)

Topic mentions per year

Topic mentions per year

2013-2017
0520132017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
BACKGROUND Lysyl oxidase-like 2 (LOXL2) catalyses collagen cross-linking and is implicated in the pathogenesis of idiopathic… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
2017
2017
Inhibition of apoptosis signal-regulating kinase 1, a serine/threonine kinase, leads to improvement in inflammation and fibrosis… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2017
2017
Background. Portal hypertension, an elevation in the hepatic venous pressure gradient (HVPG), can be used to monitor disease… (More)
  • table 1
  • table 2
  • figure 1
Is this relevant?
2017
2017
Simtuzumab, a monoclonal antibody inhibitor of extracellular matrix enzyme lysyl oxidase-like-2, showed preclinical promise and… (More)
Is this relevant?
2017
2017
LESSONS LEARNED The safety profile in the patient groups who received FOLFIRI and simtuzumab did not differ from that in the… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
2017
2017
 
Is this relevant?
2017
2017
The overall prognosis of patients with idiopathic pulmonary fibrosis (IPF) is poor, with a 5-year survival of approximately 20… (More)
Is this relevant?
2016
2016
BACKGROUND Chronic liver injury can result in fibrosis that may progress over years to end-stage liver disease. The most… (More)
Is this relevant?
2014
2014
LESSONS LEARNED The safety profile in the gemcitabine/simtuzumab group was similar to that in the gemcitabine/placebo group.The… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
2014
2014
Taking the immunomodulator simtuzumab with gemcitabine did not statistically significantly increase progression-free survival in… (More)
Is this relevant?